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Induction of labour is performed frequently for a variety of
obstetric conditions. However, in the presence of an
unfavourable cervix, the procedure can be prolonged and
result in increased caesarean section (CS) rates. Therefore
agents that cause cervical softening and dilatation are used
before formal induction of labour. The most common agents
used for this purpose are the prostaglandin E2 (PGE2) series or
dinoprostone (Pharmacia, USA). These agents are expensive
and require refrigeration, making their use in poor countries
prohibitive. Recently, there has been interest in the off-label
(non-registered) use of misoprostol (Cytotec, Searle, USA), a
PGE1 analogue, for cervical ripening and induction of labour.
1,2
Misoprostol is widely used for first- and second-trimester
termination of pregnancy and for the management of
postpartum haemorrhage.1 Most centres in South Africa,
however, have taken a cautious approach to its use for
induction of labour at term, despite the fact that numerous
clinical trials and a recent meta-analysis have demonstrated its
efficacy.2-4 Further, the American College of Obstetricians and
Gynecologists (ACOG) guidelines recommend that
misoprostol, at a dose of 25 µg 3 - 6-hourly, is effective for the
induction of labour (level A evidence), and that 50 µg 6-hourly
may be appropriate in some situations, although an increased
risk of complications has been reported (level B evidence).5
C o n t roversy over the use of misoprostol at term exists
because of the risks of hyperstimulation and lack of information
about the appropriate dosage and route of administration.1 We
t h e re f o re decided to compare the efficacy of misoprostol with
that of dinoprostone for induction of labour in near-term and
term pregnancies, in carefully selected patients.
Methods
This prospective study was conducted at King Edward VIII
Hospital (KEH), Durban. Institutional ethical permission was
obtained and 400 women with viable term or near-term
pregnancies who fulfilled the criteria for induction of labour
were enrolled.
Women who had had a previous CS and those with a
malpresentation, a non-reassuring electronic fetal heart rate
recording, a Bishop’s score of ‡ 6 and parity ‡ 5 were excluded.
On enrolment, women were allocated to two groups by
opening sequentially numbered opaque envelopes, which had
cards with computer-generated numbers stating the method of
induction.
The control group received dinoprostone (Prandin gel).
Administration followed standard methods, viz. 1 mg was
inserted into the posterior vaginal fornix and repeated 6-hourly
for up to three doses if contractions were inadequate. If labour
was not established at the end of the third dose, a consultant
reviewed the indication for induction and a decision was made
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Objective. To compare the safety and efficacy of misoprostol
with that of dinoprostone for the induction of labour at term,
or near term.
Design. Three hundred and ninety-six women with term
pregnancies were randomised to receive either oral or vaginal
misoprostol, or dinoprostone. Women who had had a
p revious caesarean section (CS) or those with a malpre s e n t a t i o n
or who were parity ‡ 5, were excluded. The control group
received dinoprostone 1 mg inserted in the posterior fornix
and repeated 6-hourly to a maximum of three doses. The
study group received either oral misoprostol 20 µg 2-hourly
to a maximum of four doses (80 µg), or vaginal misoprostol
25 µg in the posterior fornix with a switch to the oral
misoprostol regimen if there was no change in the Bishop’s
score or no palpable uterine contractions.
Results. There was no significant difference in vaginal
delivery rate within 24 hours between the groups (58.1% v.
58%, p = 0.633). There were no significant differences in CS
rates between the groups; however, more CSs were
performed for fetal distress in the misoprostol group than in
the dinoprostone group (28% v. 25%). There was a
significantly higher incidence of hyperstimulation in the
vaginal misoprostol group (21.4%) than in the other two
groups (oral misoprostol 16.5%, dinoprostone 8.9%) (p =
0.004). The incidence of meconium staining of liquor was
comparable between the groups.
Conclusions. In selected women, the efficacy of misoprostol
for the induction of labour at term is similar to that of
dinoprostone but misoprostol is associated with a higher
incidence of hyperstimulation.
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as to whether to perform a CS or initiate induction a few days
later.
If uterine contractions were considered adequate, progress
of labour was managed by standard methods.
The study group received misoprostol either orally or
vaginally. Oral administration consisted of a 200 µg tablet
dissolved in 200 ml tap water (1 µg/ml), and administered in a
dosage of 20 ml (20 µg) every 2 hours until adequate contractions
were achieved or a maximum of 80 ml (80 µg) was given.
Vaginal misoprostol (25 µg) tablets prepared by the hospital
pharmacy were inserted in the posterior fornix, and the cervix
was assessed after 4 hours for any change in the Bishop’s score
or palpation of moderate to strong contractions abdominally. If
neither was achieved, a switch to oral administration to a
maximum of 60 µg (three doses) was initiated. If labour was
not achieved, a consultant reviewed the indication as in the
control group.
Uterine contractions were observed using a combination of
abdominal palpation and uterine cardiotocodynamometry. The
hyperstimulation syndrome was defined as a combination of
hypersystole and/or tachysystole with abnormal heart rate
changes. Management of these conditions followed the
standard labour ward procedures at KEH.
The standard labour protocol was used for monitoring of
patients. This consisted of pre- and post-misoprostol
administration cardiotocographic assessment.
The primary outcome measure was the initiation of labour
and delivery within 24 hours.
Secondary outcomes were induction to delivery time,
meconium staining of liquor, non-reassuring fetal heart rate
patterns, hyperstimulation, mode of delivery, perinatal
mortality, and average dose requirements.
Statistics
Statistical methods used included Pearson’s chi-square and
Fisher’s exact tests to measure comparisons. A sample size of
396 achieves a power of 98%, at the significance level of 0.05.
Results
Four hundred women were enrolled. There was incomplete
documentation in 4 cases, therefore analysis of the data will
show variation in the numbers of cases. Table I shows the
characteristics of the women at enrolment. The commonest
indication for induction was postdatism (N = 131). The groups
were all matched in terms of maternal characteristics and
demographic data.
Failed induction
Labour was successfully initiated and delivery achieved within
24 hours in 373 (94%) of the 396 patients (inclusion of caesarean
sections). Eleven patients (5.7%) from the dinoprostone arm
(group 1) and 12 (6%) from the misoprostol arm (group 2), i.e.
23 in total, did not go into labour. Of the 11 failed inductions in
group 1, 3 subsequently went into spontaneous labour within
72 hours and the remaining 8 had subsequent re-insertions of
dinoprostone and had CSs for failure to progress in labour or
fetal distress.
Table I. Demographic details and indications for labour (range)
Oral misoprostol Vaginal + oral Dinoprostone
alone (N = 103) misoprostol (N = 100) (N = 193)
Age (years) 26 25 26
Parity 1 (1 - 2) 1 (1 - 2) 1 (1 - 3)
Gestational age (weeks) 38 (28 - 40) 38 (27 - 42) 38 (26 - 42)
Bishop’s score at various
time intervals (hours)
Trial entry — 0 h 5 (3 - 5) 4.5 (4 - 5) 5 (4 - 5)
6 h 6 (5 - 7) 7 (6 - 7) 7 (5 - 7)
12 h 9 (7 - 9) 9 (7 - 10) 9 (7 - 10)
24 h 9 (7 - 12) 9 (8 - 13) 9 (8 - 13)
Indications for induction
Gestational hypertension 26 40 55
Pre-eclampsia 17 20 45
Post dates 41 25 65
PROM 8 7 16
Fetal growth restriction 12 13 37
Intrapartum haemorrhage 0 0 2
Intra-uterine death 2 4 2
Others 2 1 4
PROM = premature rupture of membranes
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Of 12 women with failed inductions in the misoprostol
group, 4 went into spontaneous labour within 72  hours while
6 had further insertions of dinoprostone; 8 of the 12 had
vaginal deliveries and all were delivered within a week of trial
entry.
Mode of delivery
Overall, there were 113 vaginal deliveries (58.1%) and 80 CS
deliveries (40%) in the dinoprostone group. In the misoprostol
group, 118 women (58%) had vaginal deliveries and 81 (40%)
had CSs. The overall vaginal delivery rate was 58% (calculated
from 231 vaginal deliveries), while the CS rate was 40%
(calculated from 161 CS deliveries). The difference was not
statistically different, with p - values of 0.45 and 0.73
respectively.
Overall, vaginal delivery was achieved in 60.8% of women
(N = 226) and CS in 142 (38%). There was no statistical
difference between the groups, as shown in Table II (p = 0.633).
Neonatal outcome
Of the 396 patients in the study, 5 had an intrauterine death,
leaving 391 women with a live fetus at term who underwent
induction of labour. In 388 cases neonatal outcome was good.
Of the 3 perinatal deaths, 2 were in the misoprostol group and
1 in the dinoprostone group. In the misoprostol group a
stillborn baby (weighing 850 g) was born to a woman with
severe pre-eclampsia who had an induction for uncontrollable
hypertension at 28 weeks’ gestation; the second stillbirth
occurred in a primigravida who underwent caesarean section
for a non-reassuring fetal heart rate and cephalopelvic
disproportion, approximately 8 hours after insertion of vaginal
misprostol. The perinatal death in the dinoprostone group
occurred after a caesarean section for delay in the second stage
of labour. The baby had poor Apgar scores and despite
resuscitation died 3 days later.
There were no significant differences between the two
groups in terms of neonatal outcome.
Meconium staining of liquor
Meconium staining was found in 16 women in the
dinoprostone group (8.2%) and 22 in the misoprostol group
(10.9%) (p = 0.33).
CS delivery for fetal distress
Fetal distress accounted for 39 of 80 CSs in the dinoprostone
group (0.5%) and 43 of 81 CS deliveries in the misoprostol
group (0.52%) (p = 0.51).
Hyperstimulation
There were 55 cases of hyperstimulation, 17 in the
dinoprostone group and 38 in the misoprostol group. The
difference between the two groups was statistically significant
(p = 0.004); 21.4% of vaginal misoprostol patients had
hyperstimulation compared with 16.5% in the oral group, and
8.9% in the dinoprostone group.
Induction to delivery time
The average induction to delivery time was 17 hours in the
dinoprostone group and 16 hours in the misoprostol group (p =
0.493).
Average dose required
The average dose utilised was 2 mg in the dinoprostone group,
whereas in the misoprostol arm of study the average dose was
at 60 µg, which is equivalent to three ingestions/insertions.
Other variables inclusive of hospital stay (4 - 5 days), age,
Bishop’s score, and cervical dilatation at CS were not
statistically different.
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Table II. Obstetric outcomes
Vaginal + Misoprostol Vaginal
Oral oral v. misoprostol v.
misoprostol misoprostol Dinoprostone dinoprostone oral
(N = 103) (N = 100) (N = 193) (p-value) misoprostol (p-value)
Vaginal delivery 24 hrs 57 54 104 0.633 0.776
CS rate 41 40 80 0.732
Number of doses (mean) 3 2 2 0.076 0.000
CS fetal distress 21 23 39 0.517
Tachysystole 16 21 9 0.004 0.391
Meconium staining of liquor 9 13 16 0.33 0.341
Oxytocin 23 24 60 0.065 0.868
Failed induction 8 4 11 0.517 0.248
Ruptured uterus - - -
Admit to nursery 12 21 29 0.167
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Maternal morbidity
There were 2 cases of morbidity in the dinoprostone group.
One woman developed a postpartum haemorrhage (PPH)
following CS and  the other had a total hysterectomy for
puerperal sepsis which developed following a CS.
There was 1 case of morbidity in the misoprostol group. A
hysterectomy was performed for PPH following a CS.
Discussion
Our study, using doses of < 50 µg of misoprostol and
conducted in a setting of poor resources and a busy labour
ward performing 10 000 deliveries per year, has shown that
misoprostol is as effective as the standard method of induction
of labour at term, viz. dinoprostone. Labour was successfully
achieved in 373/396 women (94%); 58% of patients in the
dinoprostone arm and 58% in the misoprostol arm of the study
were successfully delivered vaginally. These results confirm
recent reports and have positive implications for health
services that are poorly resourced as misoprostol is cheap, does
not need refrigeration, and is easily administered either orally
or vaginally.6-9
The higher efficacy of misoprostol after vaginal
administration may be due to the greater systemic
bioavailability of vaginally administered misoprostol; peak
levels are attained more slowly but sustained for longer periods
due to avoidance of first bypass hepatic and/or pre s y s t e m i c
g a s t rointestinal metabolism. More o v e r, there is probably a
d i rect effect on the cervix leading to uterine contractility.1 0 , 11
Despite concerns about hyperstimulation with the use of
misoprostol for term induction of labour, the regimens utilised
have not been associated with an increase in perinatal
mortality rates or perinatal asphyxia. We had strict criteria for
trial entry. Women with previous uterine surgery, a
malpresentation, and 5 or more pregnancies were excluded. We
had no cases of uterine rupture. There have been reports on the
use of misoprostol to induce labour in women with previous
CS and a recent retrospective study found significantly more
cases of uterine rupture, or dehiscence after cervical ripening
with misoprostol than with oxytocin or prostaglandin E2.12
In our study, the incidence of hyperstimulation was higher
in the vaginal misoprostol group (21.4%) than in the oral group
(16.5%) and the dinoprostone group (8.9%). The difference
between the vaginal misoprostol and dinoprostone groups was
statistically significant (p = 0.004). The doses used varied from
20 µg to a maximum of 85 µg. An interim analysis after the
enrolment of 200 patients did not show any statistical
significance between the groups. Larger numbers are required
to establish the difference between groups and it has been
reported that 4 000 patients would need to be recruited,13
necessitating a multicentred study.
The incidence of meconium staining of liquor was
comparable between the two groups (p = 0.33). None of the
cases displayed severe grades of meconium staining. Previous
reviews have shown a trend towards more meconium passage
with misoprostol than with other induction agents. 2 It is not
clear  whether meconium is due to hyperstimulation or to a
direct effect of misoprostol on the gastrointestinal tract. In our
study, many women had inductions for postdatism and pre-
eclampsia, conditions not uncommonly associated with
meconium staining. Furthermore, many women in our setting
take traditional herbal medications during late pregnancy to
facilitate labour. This has been shown to be associated with a
high incidence of meconium.14 Trials involving larger numbers
of patients may answer concerns about meconium staining of
liquor and hyperstimulation. The findings of this study,
however, did not impact on perinatal mortality or CS rates.
The CS rates in our study were high, but the overall CS rate
at KEH is 25%. Invasive monitoring during labour is not
practised because of the high prevalence of HIV and this may
also account for higher CS rates.
Our study was  also designed to address complications
associated with misoprostol in our environment and the results
are similar to those of studies conducted in other centres with
an overall, uniform finding of low complication rates.6-9
At the dose described, oral misoprostol is as effective as
vaginal and oral administration combined. The cost-benefit
ratio of misoprostol (approximately R1 - R2) over dinoprostone
(approximately R250 - R350) for the induction of labour at
term, is a strong argument for using misoprostol. It should be
noted, however, that as uterine hyperstimulation occurred
more frequently when misoprostol was used, the fetal heart
rate should be monitored electronically and continuously when
this drug is used at term. Trials with larger numbers of patients
are required to establish optimal and safe doses.
References
1. Hofmeyr GJ. Induction of labour with misoprostol. Curr Opin Obstet Gynecol 2001; 13: 577-
581.
2. Hofmeyr GJ, Gulmezoglu AM. Vaginal misoprostol for induction of labour (Cochrane
Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
3. Hofmeyr GJ, Gulmezoglu AM, Aifirevic M. Misoprostol for induction of labour. Br J Obstet
Gynaecol 1999; 106: 198-203.
4. Sanchez-Ramos L, Kaunitz AM, Wears RL, Delke I, Gaudier FL. Misoprostol for cervical
ripening and labour induction: a systematic review of the literature. Clin Obstet Gynecol 2000;
43: 475-488.
5. American College of Obstetricians and Gynecologists. Response to Searle’s drug warning on
misoprostol. ACOG Committee Opinion 248. Washington, DC, December 2000.
6. Le Roux PA, Olarogun JO, Penny J, Anthony J. Oral and vaginal misoprostol for induction of
labour. Obstet Gynecol 2002; 99: 201-205.
7. Hofmeyr GJ, Alfirevic Z, Matonlodze B. Titrated oral misoprostol for induction of labour: a
multi-centre randomised trial. Br J Obstet Gynaecol 2001; 108: 238-243.
8. Wing DA, Rahall A, Jones MM, Goodwin TM. Misoprostol: An effective agent for cervical
ripening and labour induction. Am J Obstet Gynecol 1995; 172: 1811-1816.
9. Shelly A, Danielian P, Templeton A. Sublingual misoprostol for induction of labour at term.
Am JObstet Gynecol 2002; 186: 72-76.
10. Zieman M, Fong SK, Berowitz NL, Bankster D, Darney PD. Absorption kinetics of
misoprostol with oral or vaginal administration. Obstet Gynecol 1999; 93: 275-280.
11. Danielsson GK, Marions L, Rodriguez A, Spur BW, Wong PWK, Bygdeman M. Comparison
between oral and vaginal administration of misoprostol on uterine activity. Obstet Gynecol
1999; 93: 275-280.
12. Hill DA, Chez RA, Quinlan J, Fuentes A, LaCombe J. Uterine rupture and dehiscence
associated with intravaginal misoprostol cervical ripening. J Reprod Med 2000; 45: 823-826.
13. Le Roux PA, Olarugun JO, Penny J, Anthony J. Oral and vaginal misoprostol compared with
dinoprostone for induction of labour: a randomised controlled trial. Am J Obstet Gynecol 2002;
99: 201-205.
14. Mabina H, Moodley J, Pitsoe SB. The use of traditional herbal medication in pregnancy. Trop
Doct 1997; 27: 84-85.
Accepted 8 November 2002.
